Stocks and Investing
Stocks and Investing
Mon, March 11, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, March 8, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, March 7, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Hartaj Singh Maintained (VRTX) at Buy with Increased Target to $230 on, Mar 7th, 2019
Hartaj Singh of Oppenheimer, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $200 to $230 on, Mar 7th, 2019.
Hartaj has made no other calls on VRTX in the last 4 months.
There are 3 other peers that have a rating on VRTX. Out of the 3 peers that are also analyzing VRTX, 1 agrees with Hartaj's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Christopher Raymond of "Raymond James" Downgraded from Buy to Hold on, Wednesday, January 2nd, 2019
These are the ratings of the 2 analyists that currently disagree with Hartaj
- Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Decreased Target to $205 on, Friday, January 4th, 2019
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $210 on, Wednesday, December 19th, 2018
Contributing Sources